| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 3.7K | 6.7% | 5.0% |
| Total Income | 3.7K | 6.7% | 5.0% |
| Expenditure | 3.7K | 4.2% | 12.1% |
| PBT | -64.00 | 74.1% | 70.5% |
| Net Profit | -118.80 | 167.3% | 2482.6% |
| OPM | 0.17% | 2.44pp | 6.36pp |
| NPM | -3.17% | 8.20pp | 3.04pp |
| EPS | -0.10 | 166.7% |
Viatris Reports Q2 2026 Financial Results with $3.8 Billion Revenue and Raised Guidance
06 Aug 2026 · 6 Aug, 5:34 pm
Summary
Viatris reported second-quarter 2026 total revenues of $3.8 billion, a 5% increase on a reported basis and 3.5% operationally compared to the prior year, driven by new product sales and growth in Greater China. The company's Adjusted EBITDA rose 8% operationally to $1.2 billion, with Adjusted EPS increasing 9% operationally to $0.69. Despite a U.S. GAAP net loss of $119 million, largely due to a non-cash charge for the Tyrvaya® sale, Viatris raised its full-year 2026 financial guidance midpoints across all metrics, signaling confidence in its business momentum and strategic execution.
Key Highlights
- 1
Viatris reported Total Revenues of $3.8 billion for the second quarter of 2026, representing 5% reported growth compared to the second quarter of 2025.
- 2
The company achieved an Adjusted EBITDA of $1.2 billion, an increase of 8% operationally compared to the second quarter of 2025.
- 3
Second-quarter 2026 U.S. GAAP net loss was $119 million, impacted by a non-cash charge related to the planned sale of Tyrvaya® product rights.
- 4
Adjusted EPS for the second quarter of 2026 was $0.69, an increase of 9% on an operational basis compared to the prior year period.
- 5
Viatris advanced key pipeline milestones, including the U.S. FDA approval of Gwyn LoTM and the sale of global rights to Tyrvaya®.
- 6
The company is raising its 2026 financial guidance midpoints for all key metrics, reflecting strong first-half results and confidence in future performance.
- 7
Free cash flow, excluding transaction-related and restructuring-related costs, was $449 million for the second quarter of 2026.
Management Comments
Scott A. Smith
Our second-quarter results reflect another quarter of strong execution and reinforce the momentum we're building across our business. Commercial execution, pipeline progress and the early benefits of our enterprise-wide strategic review continue strengthening our business and improving our financial performance. Our strong first-half results give us the confidence to raise our full-year guidance. We expect a more balanced operating environment in the second half of the year and we remain focused on disciplined execution, investing behind our future growth drivers and creating long-term value for patients and shareholders.
Paul Campbell
We delivered another strong quarter of Total Revenues and Adjusted EBITDA growth over the prior year, reflecting continued strong operational execution. At the same time, we continued to execute on our balanced capital allocation strategy, returning approximately $550 million to shareholders, including approximately $270 million of share repurchases occurring through early August. In addition, we further strengthened our balance sheet and reduced our gross leverage ratio to 2.9x.
Informational and educational content only. Not investment advice.